Nelson LaMarche is an Assistant Professor in the Department of Pathology and the Cancer Biology Institute at Yale University. He obtained his Ph.D. in Immunology at Harvard University under Drs. Michael Brenner and Lydia Lynch studying the role of the immune system in controlling adipose tissue physiology and metabolic homeostasis. He then performed postdoctoral studies at the Icahn School of Medicine at Mount Sinai under Dr. Miriam Merad, where he developed a translational research program focused on myeloid cells in cancer immunotherapy. While at Mount Sinai, Nelson made the notable discovery that the cytokine interleukin-4 (IL-4) is produced within bone marrow during lung cancer and drives the development of immunosuppressive, tumor-promoting myeloid cells; he translated these results into a clinical trial of the IL-4R blocking antibody dupilumab (marketed commercially as Dupixent) in advanced lung cancer, and highlighted this agent as a potential novel immunotherapy (LaMarche, et al., 2024, Nature). His current research focuses on developing myeloid-targeted immunotherapies for cancer, with a particular emphasis on how tumors remotely communicate with distant organs to alter normal physiology and subvert the antitumor immune response.